TrialSignal
Clinical trial intelligence report
An Open Trial of a Novel Pharmacotherapy for Habit Modification in Anorexia Nervosa
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jun 13, 2026
NCT ID
NCT06518941
Status
NOT_YET_RECRUITING
Phase
PHASE2
Sponsor
New York State Psychiatric Institute
Executive brief
Investment-Ready Snapshot
The purpose of this study is to test the feasibility and tolerability of donepezil in a small group of patients with anorexia nervosa (AN). Study participants will be receiving care at the New York State Psychiatric Institute Eating Disorders Unit. Study medication will be increased from 1 mg per day to a maximum of 5 mg per day for up to 8 weeks. Participants will be closely monitored for side effects by a research psychiatrist every week, in addition to the regular clinical monitoring they receive during inpatient treatment. The study will also include assessments of habit strength to measure any changes in maladaptive eating habits over the course of the treatment.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT06518941
Indication
Anorexia Nervosa
Modality
small molecule
Target
Donepezil
Intervention
Donepezil
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.